Correction to: Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
作者信息
Mease Catherine, Miller Kathleen L, Fermaglich Lewis J, Best Jeanine, Liu Gumei, Torjusen Erika
机构信息
Office of Orphan Products Development, Office of the Commissioner, US Food and Drug Administration, 10903 New Hampshire Ave, 20993, Silver Spring, MD, USA.
Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, 10903 New Hampshire Ave, 20993, Silver Spring, MD, USA.
出版信息
Orphanet J Rare Dis. 2024 Mar 21;19(1):131. doi: 10.1186/s13023-024-03136-7.
Abstract
摘要
相似文献
1
Correction to: Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.对《美国食品药品监督管理局罕见儿科疾病优先审评券计划头十年分析：指定、疾病与药物研发》的勘误
Orphanet J Rare Dis. 2024 Mar 21;19(1):131. doi: 10.1186/s13023-024-03136-7.
2
Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.FDA 罕见儿科疾病优先审评券计划头十年分析：指定、疾病和药物研发。
Orphanet J Rare Dis. 2024 Feb 25;19(1):86. doi: 10.1186/s13023-024-03097-x.
3
Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.倡导者呼吁长期延长美国食品药品监督管理局（FDA）的罕见儿科疾病优先审评计划：联邦代金券计划被认为有助于缩短药物审评和批准周期。
Am J Med Genet A. 2017 Jan;173(1):7-8. doi: 10.1002/ajmg.a.38091.
4
Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.优先审评券计划对罕见儿科疾病药物研发的影响。
Health Aff (Millwood). 2019 Feb;38(2):313-319. doi: 10.1377/hlthaff.2018.05330.
5
FDA's Expedited Programs and Their Impact on the Availability of New Therapies.美国食品药品监督管理局的加速计划及其对新疗法可及性的影响。
Ther Innov Regul Sci. 2017 Jan;51(1):24-28. doi: 10.1177/2168479016666587. Epub 2016 Sep 27.
6
Priorities for the Priority Review Voucher.优先审评券的优先事项。
Am J Trop Med Hyg. 2017 Jan 11;96(1):14-15. doi: 10.4269/ajtmh.16-0600. Epub 2016 Aug 29.
7
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.利用美国食品和药物管理局（FDA）四十年来的孤儿药指定来描述罕见病药物开发的趋势：在治疗罕见肿瘤、神经和儿科疾病的药物开发方面取得了显著增长。
Orphanet J Rare Dis. 2021 Jun 9;16(1):265. doi: 10.1186/s13023-021-01901-6.
8
Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.肿瘤学药物标签修订频率与美国食品药品监督管理局（FDA）产品分类之间关系的研究。
Am J Public Health. 2009 Sep;99(9):1693-8. doi: 10.2105/AJPH.2008.141010. Epub 2009 Apr 16.
9
10
US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.美国热带病优先审评券：促进药物研发和可及性的经验教训。
Health Aff (Millwood). 2021 Aug;40(8):1243-1251. doi: 10.1377/hlthaff.2020.02273.
本文引用的文献
1
Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.FDA 罕见儿科疾病优先审评券计划头十年分析：指定、疾病和药物研发。
Orphanet J Rare Dis. 2024 Feb 25;19(1):86. doi: 10.1186/s13023-024-03097-x.
Zotero 插件